Trial Profile

Bioequivalence trial of extended-release ondansetron (RHB 102) vs Zofran

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Sep 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ondansetron (Primary)
Indications Chemotherapy-induced nausea and vomiting; Radiotherapy-induced nausea and vomiting
Focus Pharmacokinetics; Registrational
Sponsors RedHill Biopharma

Most Recent Events

30 Apr 2014 RedHill Biopharma plans to submit a European marketing application for RHB-102 for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting in cancer patients in Q3 of 2014 based on the positive results from this study.
07 Apr 2014 RedHill Biopharma expects to report results in July 2014.
07 Apr 2014 Status changed from planning to recruiting, as reported in a RedHill Biopharma media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com